RxDoctor Payments Data

Erika Cortes, APRN

Psychiatric/Mental Health · Longwood, FLNPI 1396392304

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 65 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$790
  • Bioxcel Therapeutics, Inc.$211
  • Acadia Pharmaceuticals Inc$99
  • Neurocrine Biosciences, Inc.$89
  • Avanir Pharmaceuticals, Inc.$88
  • Teva Pharmaceuticals USA, Inc.$70
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$1,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,365 in reported general payments places this provider in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$308,203
Medicare patients
728
Services billed
4,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine345$499,966
NuplazidPimavanserin Tartrate11$55,098
SecuadoAsenapine12$12,223
Trazodone Hcl214$2,598
Duloxetine Hcl105$2,579
PremarinEstrogens, Conjugated24$2,547
Mirtazapine88$2,249
Gabapentin60$1,804
Divalproex Sodium48$1,632
Lorazepam148$1,305
Sertraline Hcl102$942
Buspirone Hcl42$611
Haloperidol11$592
Clonazepam62$552
Bupropion XlBupropion Hcl11$520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$88$499,966345 claims
Acadia Pharmaceuticals IncNuplazid$99$55,09811 claims
PfizerPremarin$19$2,54724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →